Infantile hemangiomas (IHs) are common neoplasms composed of proliferating endothelial-
like cells. Despite the relative frequency of IH and the potential severity of complications …

METHODS: We searched Embase and Medline databases (2007–July 2014) and
unpublished data from the manufacturer of Hemangiol/Hemangeol (marketed pediatric …

To systematically review the literature evaluating efficacy and adverse events of propranolol
treatment for infantile hemangiomas, we searched the MEDLINE and Cochrane databases …

Background The success of oral propranolol for treatment of infantile hemangiomas (IHs)
has led practitioners to use topical β‐blockers. In preterm infants, clinicians frequently turn to …

Infantile hemangiomas (IH) are the most common tumors in children, with an estimated
incidence of 4% to 5%, with higher prevalence noted in Whites, girls, and preterm/low-birth …

Propranolol has recently been reported to be a highly effective treatment for infantile
hemangioma (IH) and is emerging as a first‐line therapy. This study reports the observations …

Infantile haemangioma (IH) are vascular tumours with a unique growth dynamic, mostly
absent at birth, growth in the first months followed by involution over several years, often …

Although the efficacy of propranolol for the treatment of infantile hemangiomas (IHs) has
been well documented, there is a paucity of clinical data regarding the safety and tolerance …

Context: Propranolol, atenolol, and ICI118, 551 are non-selective β-adrenergic receptor
(AR), β1-AR, and β2-AR antagonists, respectively. Objective: We investigated the efficacy of …

Background Retinopathy of prematurity (ROP) is a vision‐threatening disease of preterm
neonates. The use of beta‐adrenergic blocking agents (beta‐blockers), which modulate the …